Phase II Study of CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma Intervention: Biological: ATLCAR.CD30 T cells Sponsor: UNC Lineberger Comprehensive Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials